We are live on
!
Find out more
Grantham, Mayo, Van Otterloo & Co (GMO) Portfolio holdings
AUM
$44.4B
1-Year Est. Return
36.05%
This Fund
S&P 500
This Quarter
Est. Return
-1.68%
1 Year Est. Return
+36.05%
3 Year Est. Return
+84.6%
5 Year Est. Return
+116.4%
10 Year Est. Return
+513.43%
AUM
$39.1B
AUM Growth
-$26.3M
(-0.07%)
Cap. Flow
+$1.59B
Cap. Flow
% of AUM
4.07%
Top 10 Holdings %
Top 10 Hldgs %
39.91%
Holding
738
New
84
Increased
295
Reduced
215
Closed
110
Avg Time Held Equity + Options
10.2
quarters
Top 10 Avg Time Held Equity + Options
13.8
quarters
Top 20 Avg Time Held Equity + Options
20.4
quarters
Avg Time Held Equity only
10.2
quarters
Top 10 Avg Time Held Equity only
13.8
quarters
Top 20 Avg Time Held Equity only
20.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$499M |
| 2 |
Synopsys
SNPS
|
+$411M |
| 3 |
Microsoft
MSFT
|
+$380M |
| 4 |
Netflix
NFLX
|
+$354M |
| 5 |
Cigna
CI
|
+$177M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$546M |
| 2 |
Wells Fargo
WFC
|
+$453M |
| 3 |
Permian Resources
PR
|
+$229M |
| 4 |
Elevance Health
ELV
|
+$195M |
| 5 |
NVIDIA
NVDA
|
+$97.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.72% |
| 2 | Healthcare | 23.65% |
| 3 | Communication Services | 11.87% |
| 4 | Financials | 10.29% |
| 5 | Consumer Discretionary | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Microsoft
MSFT
$3.97T
| $2.29B | 5.85% |
6,176,138
+908,452
| +17% | +$380M |
2013 Q2
51 quarters
|
|
2
Alphabet (Google) Class A
GOOGL
$4.3T
| $1.98B | 5.08% |
6,900,577
+228,986
| +3% | +$71.9M |
2015 Q4
41 quarters
|
|
3
Johnson & Johnson
JNJ
$630B
| $1.78B | 4.55% |
7,278,866
+189,727
| +3% | +$44.2M |
2013 Q2
51 quarters
|
|
4
Apple
AAPL
$4.91T
| $1.76B | 4.5% |
6,937,574
+230,457
| +3% | +$60M |
2013 Q2
51 quarters
|
|
5
Meta Platforms (Facebook)
META
$1.83T
| $1.76B | 4.5% |
3,073,041
+164,479
| +6% | +$105M |
2018 Q1
32 quarters
|
|
|
6
Lam Research
LRCX
$399B
| $1.48B | 3.77% |
6,904,206
-2,439,874
| -26% | -$546M |
2019 Q3
26 quarters
|
|
7
Amazon
AMZN
$2.83T
| $1.3B | 3.32% |
6,229,375
-124,038
| -2% | -$27.3M |
2018 Q3
30 quarters
|
|
8
Thermo Fisher Scientific
TMO
$243B
| $1.23B | 3.15% |
2,502,206
+90,143
| +4% | +$48.9M |
2024 Q2
7 quarters
|
|
9
Broadcom
AVGO
$1.73T
| $1.04B | 2.65% |
3,348,517
+211,786
| +7% | +$69.7M |
2021 Q1
20 quarters
|
|
10
US Bancorp
USB
$88.9B
| $994M | 2.54% |
19,113,643
+712,639
| +4% | +$39.2M |
2017 Q2
35 quarters
|
|
11
Texas Instruments
TXN
$259B
| $983M | 2.51% |
5,061,047
+173,227
| +4% | +$35.1M |
2016 Q2
39 quarters
|
|
12
Visa
V
$724B
| $918M | 2.35% |
3,036,116
+386,559
| +15% | +$124M |
2017 Q3
34 quarters
|
|
13
Abbott
ABT
$172B
| $915M | 2.34% |
8,910,945
+428,392
| +5% | +$48.4M |
2013 Q2
51 quarters
|
|
14
UnitedHealth
UNH
$340B
| $855M | 2.19% |
3,158,451
+488,292
| +18% | +$145M |
2013 Q2
51 quarters
|
|
15
Merck
MRK
$359B
| $844M | 2.16% |
7,013,777
+143,632
| +2% | +$16.6M |
2016 Q3
38 quarters
|
|
16
Salesforce
CRM
$189B
| $826M | 2.11% |
4,425,552
+321,519
| +8% | +$66.6M |
2020 Q3
22 quarters
|
|
17
Accenture
ACN
$128B
| $774M | 1.98% |
3,902,335
+281,066
| +8% | +$65.5M |
2013 Q2
51 quarters
|
|
|
18
Cigna
CI
$74.6B
| $693M | 1.77% |
2,598,218
+640,084
| +33% | +$177M |
2020 Q4
21 quarters
|
|
19
Eli Lilly
LLY
$1.05T
| $690M | 1.76% |
749,815
+10,541
| +1% | +$10.7M |
2013 Q2
51 quarters
|
|
20
KLA
KLAC
$255B
| $679M | 1.74% |
4,612,020
-475,550
| -9% | -$69.6M |
2017 Q3
34 quarters
|
|
21
Hilton Worldwide
HLT
$73.5B
| $675M | 1.73% |
2,219,281
-120,732
| -5% | -$36.6M |
2020 Q2
23 quarters
|
|
22
Coca-Cola
KO
$379B
| $630M | 1.61% |
8,279,748
-528,730
| -6% | -$40M |
2013 Q2
51 quarters
|
|
23
Constellation Brands
STZ
$20.8B
| $604M | 1.54% |
4,025,780
+161,746
| +4% | +$25M |
2021 Q2
19 quarters
|
|
24
TJX Companies
TJX
$153B
| $593M | 1.52% |
3,712,526
-85,993
| -2% | -$13.4M |
2013 Q2
51 quarters
|
|
25
Intuitive Surgical
ISRG
$150B
| $567M | 1.45% |
1,230,930
+45,020
| +4% | +$22.8M |
2022 Q2
15 quarters
|
|
Similar funds
GAM
Grantham, Mayo, Van Otterloo & Co (GMO)'s Q1 2026 Portfolio in Review
As of Q1 2026, Grantham, Mayo, Van Otterloo & Co (GMO) held 738 positions worth $39.1B, down 0.07% from $39.1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Grantham, Mayo, Van Otterloo & Co (GMO) deployed $1.59B of net new capital in Q1 2026, opening 84 new positions and adding to 295 existing holdings. Its largest new stake was Synopsys: 910,133 shares worth $361M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 32% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Lam Research, an estimated $546M trimmed.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s largest Q1 2026 buy was Synopsys: 910,133 shares worth $361M.
- Grantham, Mayo, Van Otterloo & Co (GMO) added most to Mastercard in Q1 2026, an estimated $499M increase.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s biggest Q1 2026 reduction was Lam Research, cutting an estimated $546M.
- Grantham, Mayo, Van Otterloo & Co (GMO) fully exited Comerica in Q1 2026, selling an estimated $36.8M.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s ten largest holdings make up 40% of its $39.1B portfolio in Q1 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) opened 84 new positions and closed 110 in Q1 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio value fell 0.07% quarter-over-quarter to $39.1B.
Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.